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MyoD and NeuroD2, master regulators of myogene-
sis and neurogenesis, bind to a ‘‘shared’’ E-box
sequence (CAGCTG) and a ‘‘private’’ sequence
(CAGGTG or CAGATG, respectively). To determine
whether private-site recognition is sufficient to
confer lineage specification, we generated a MyoD
mutant with the DNA-binding specificity of NeuroD2.
This chimeric mutant gained binding to NeuroD2 pri-
vate sites but maintained binding to a subset of
MyoD-specific sites, activating part of both the mus-
cle and neuronal programs. Sequence analysis re-
vealed an enrichment for PBX/MEIS motifs at the
subset of MyoD-specific sites bound by the chimera,
and point mutations that prevent MyoD interaction
with PBX/MEIS converted the chimera to a pure
neurogenic factor. Therefore, redirectingMyoD bind-
ing fromMyoD private sites to NeuroD2 private sites,
despite preserved binding to the MyoD/NeuroD2
shared sites, is sufficient to change MyoD from a
master regulator of myogenesis to amaster regulator
of neurogenesis.INTRODUCTION
Conversion of fibroblasts, and many other cell types, to skeletal
muscle cells through expression of MyoD was the first demon-
stration of programmed transdifferentiation, with a single tran-
scription factor able to specify a cell lineage (Davis et al., 1987;
Fong and Tapscott, 2013; Tapscott et al., 1988). Subsequently,
other transcription factors have been identified with similar line-
age determining abilities, such as the ability of the NeuroD tran-
scription factors to transdifferentiate cells to neurons (Farah
et al., 2000; Lee et al., 1995; Vierbuchen et al., 2010). Both
MyoD and the NeuroD factors have a basic-helix-loop-helixCelldomain, form dimers with the E-protein family, and bind a core
CANNTG motif (Berkes and Tapscott, 2005; Chae et al., 2004);
yet, they activate distinct programs of differentiation with only
about 10% of regulated genes in common (Fong et al., 2012).
Besides the shared bHLH motif and the core DNA binding motif,
MyoD andNeuroD2 proteins have little similarity, suggesting that
their lineage specificity might be encoded in divergent regions of
the proteins. As a possible alternative to this model, our recent
chromatin immunoprecipitation sequencing (ChIP-seq) study
showed that while both factors bind to a shared E-box sequence
(CAGCTG), NeuroD2 and MyoD also had a strong binding pref-
erence for a distinct, or ‘‘private,’’ E-box binding sequences
(CAGATG and CAGGTG, respectively), and that these private
binding sites were more strongly associated with lineage-spe-
cific gene transcription (Fong et al., 2012). To assess the relative
contribution of binding-site specificity versus other regions of the
proteins, we redirected the genome-wide binding of MyoD to the
sites bound by NeuroD2 to determine whether binding site affin-
ity was sufficient to convert MyoD from a myogenic-lineage
determination factor into a neurogenic-lineage determination
factor.
RESULTS
The DNA binding specificity of MyoD and NeuroD2 is encoded
by the conserved bHLH domain (Longo et al., 2008; Ma et al.,
1994) that is 39% identical between the two factors. We there-
fore generated a MyoD chimeric protein substituted with the
NeuroD2 bHLH domain (Figure 1A). The swapped region con-
tained all of the DNA binding and dimerization surfaces as
defined by crystal structures for MyoD (Ma et al., 1994) and Neu-
roD1 (Longo et al., 2008), a NeuroD2 homolog that differs by only
two amino acids within the bHLH domain. Similar to NeuroD2,
the chimeric MD(ND2bHLH) protein, henceforth referred to as
M(N), showed increased relative activation of a reporter contain-
ing a pair of NeuroD2 private (GA) E-boxes and weak activation
of both the MyoD private (GG) and the shared (GC) E-box re-
porters (Figure 1B), whereas MyoD showed stronger activationReports 10, 1937–1946, March 31, 2015 ª2015 The Authors 1937
Figure 1. Replacement of theMyoD bHLH Domain with the NeuroD2 bHLH Domain Confers Binding to NeuroD2 Private E-boxes and Loss of
Binding to MyoD Private E-boxes
(A) Amino acid sequences of bHLH domains (underlined) are depicted for MyoD, NeuroD2, and M(N) chimera. Residues are colored as conserved (gray), similar
(black), MyoD-specific (blue), or NeuroD2-specific (green).
(B) MyoD, NeuroD2, or M(N) chimera were co-transfected with a reporter construct containing a pair of NeuroD2 private E-boxes (GA), MyoD private E-boxes
(GG), or shared E-boxes (GC). M(N) activates the GA reporter, but only weakly activates the GG and GC reporters, similar to wild-type NeuroD2. The stronger
activity of the M(N) chimera compared to NeuroD2 suggests a stronger activation domain provided by the MyoD portion. Error bars represent 1 SD.
(C) In vitro dissociation assay was performed using in-vitro-translatedMyoD, NeuroD2, or M(N) chimera. Radiolabeled probe containing a NeuroD2 private E-box
(GA), MyoD private E-box (GG), or a shared (GC) E-box, was competed with excess unlabeled oligo for the indicated amount of time. NeuroD2 andM(N) display a
slower off-rate from GA compared to both GG and GC, shown graphically for NeuroD2 (blue), M(N) chimera (green), and MyoD (red).
(D) Binding site motif enrichment logo derived fromChIP-seq in P19 cells transduced with lentivirus expressing NeuroD2, MyoD, or M(N) chimera demonstrates a
NeuroD2-like E-box preference for the chimera.
See also Figure S1.
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Figure 2. M(N) Chimera Activates Both Muscle and Neuronal Genes in P19 Cells
(A) RNA-seq from P19 cells transducedwith MyoD, NeuroD2, or M(N) chimera lentiviruses followed by neuronal differentiation demonstrates upregulation of both
MyoD and NeuroD2 target genes by the chimera. Venn diagram displays upregulated genes above log-2 fold cutoff.
(legend continued on next page)
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of the reporter with theMyoD private GG E-boxes. For both Neu-
roD2 and the M(N) chimera, this pattern of activation correlated
with a higher binding affinity to theGA E-box as demonstrated by
in vitro gel shift dissociation assays (Figure 1C). The half-life for
both NeuroD2 and the M(N) chimera bound to a GA E-box was
11 min, while for MyoD bound to a GA E-box it was <2 min.
In contrast, the half-life of NeuroD2, MyoD, and the chimera
bound to a GC E-box was only2.5 min. Together, these results
indicated that the preferential activation of the GA E-box by Neu-
roD2 correlated with relative binding affinity, and that the bHLH
domain swap conferred both the affinity and preferential activa-
tion of the NeuroD2 GA E-box to the chimeric M(N) protein.
To determine whether the chimera bound to NeuroD2 E-box
motifs in vivo, we performed ChIP-seq in P19 cells transduced
with lentiviruses expressing NeuroD2, MyoD, or M(N). At compa-
rable mRNA expression levels (see below), the total number of
binding sites was similar for MyoD and NeuroD2, while there
was roughly half the number of sites for the chimera (Table S1).
A discriminative motif enrichment analysis demonstrated
that the E-box sequence bound by the chimera closely matched
the NeuroD2 site (Figure 1D). Therefore, the chimera acquired
the E-box specificity of NeuroD2 both in vitro and in vivo.
NeuroD2 is a potent inducer of neuronal differentiation in P19
cells (Farah et al., 2000; Fong et al., 2012), while MyoD induces
only partial muscle differentiation in this cell type (Fong et al.,
2012; Skerjanc et al., 1994). We compared the transcriptional
profiles of P19 cells transduced with NeuroD2, MyoD, or M(N)
lentiviruses. Based on RNA sequencing (RNA-seq) reads, the
amount of steady-state mRNA was similar between the chimera,
MyoD, and NeuroD2 (data not shown); however, the amount of
the transduced chimeric protein was50% lower than the trans-
ducedMyoDprotein as determined bywestern blot with amono-
clonal antibody to the MyoD C terminus (Figure S1A). The
chimera demonstrated a partial activation of both the neurogenic
and myogenic programs, with 87% of genes upregulated by
the chimera also upregulated by either NeuroD2 or MyoD (Fig-
ure 2A). The chimera induced 34% of the genes upregulated
by NeuroD2 and 39% of genes upregulated by MyoD and
demonstrated strong enrichment for both neuronal and muscle
development genes (Figure 2B). Overall, the chimera had a par-
tial activation of both the neuronal and myogenic programs.
Single-cell analysis further demonstrated that the chimera
induced both muscle and neuronal genes. Transient transfection
of NeuroD2 induced robust neuronal differentiation as demon-(B) Gene ontology analysis of upregulated genes identified from RNA-seq in (A) de
by the chimera. Genes are grouped as shared between the chimera andMyoD (M(
(M(N):MD:ND2), or activated by the chimera alone (M(N)). The heatmap colors re
(C) M(N) activates expression of both muscle and neuronal differentiation marke
chimera (iv) expression vectors and an E12 construct containing a puromycin r
performed using antibodies against neuron-specific tubulin (green) and myoge
postfertilization (hpf), immunostained with anti-GFP (to label expression of the
neuron-specific anti-Elavl (Kim et al., 1996) (red). Embryo is shown in dorsal view, a
Arrowheads point to cranial ganglia. (b–d) 1-cell stage zebrafish embryos were inje
allowed to develop until 24 hpf andwere then immunostained as for control embryo
ectopic neurons outside of the neural tube.
(D) ChIP-seq for MyoD, NeuroD2, and M(N) chimera in P19 cells transduced with
chimera and both MyoD and NeuroD2. Venn diagram demonstrates degree of o
See also Figure S2. Analysis of the correlation between binding of MyoD or Neu
1940 Cell Reports 10, 1937–1946, March 31, 2015 ª2015 The Authorstrated by expression of a neuron-specific beta-tubulin and
neuronal morphology. MyoD induced MYOG expression, while
the chimera induced both neuron-specific beta-tubulin and
MYOG, but usually not within the same cell (Figure 2C). Similar
results were obtained staining for the neuronal marker internexin
and the muscle marker desmin (Figure S1B). To further test the
activity of the chimera, we expressed it in zebrafish, a model
where overexpression of myod and neurod mRNAs has been
shown to induce myogenesis and neurogenesis, respectively
(Osborn et al., 2011; Wang et al., 2000). After injection of zebra-
fish embryos with mRNAs for MyoD, NeuroD2, or the M(N)
chimera, MyoD induced widespread ectopic muscle differentia-
tion (Figure 2C; 43/43 embryos), NeuroD2 induced robust
ectopic neuronal differentiation (Figure 2C; 40/40 embryos),
and the chimera induced ectopic neuronal differentiation and
some ectopic muscle differentiation (Figure 2C; 38/38 embryos
with ectopic neurons, nine of 38 with ectopic muscle), consistent
with our findings in P19 cells. In these zebrafish embryo experi-
ments, we also did not observe co-localization of neuronal and
muscle markers.
The E-box motif analysis indicated that the chimera had lost
binding to the MyoD private GG E-box (see Figure 1D), whereas
the ChIP-seq peak locations showed that the chimera main-
tained binding at a substantial number of sites that were bound
only by MyoD, but not NeuroD2 (Figure 2D). A discriminative
motif analysis of the 200 nt region surrounding the sites bound
by both the chimera and MyoD, but not NeuroD2, revealed that
the MyoD/chimera-specific sites had a motif enrichment for
TALE transcription factors of the PBX/MEIS family, whereas
the NeuroD2-specific sites had a different PBX-like motif enrich-
ment (Figure 3A), suggesting that different PBX/MEIS-like com-
plexes might interact with MyoD and NeuroD2. A PBX/MEIS
complex has previously been shown to recruit MyoD to a subset
of binding sites through interaction with two specific domains in
MyoD outside of the bHLH region, the Cys-His rich and Helix III
domains that are N- andC-terminal to the bHLH domain, respec-
tively (Figure 3B)(Berkes et al., 2004), and this interaction with
PBX was required for the full activation of approximately 10%
of MyoD-regulated genes.
To determine whether loss of PBX/MEIS interactions would
reduce binding of the M(N) chimera to MyoD-specific sites, we
introduced point mutations in the chimera previously shown to
prevent MyoD interaction with PBX/MEIS: W96A/C98A in the
His-Cys domain (M(N)WC), S253P in Helix 3 (M(N)S), or bothmonstrates enrichment for both muscle and neuronal development categories
N):MD), sharedwith NeuroD2 (M(N):ND2), sharedwith bothMyoD andNeuroD2
present –log10 (enrichment p values).
rs. P19 cells were transfected with control (i), MyoD (ii), NeuroD2 (iii), or M(N)
esistance gene. Following selection and differentiation, immunostaining was
nin (red), with DAPI nuclear stain (blue). (a) Control zebrafish embryo, 24 hr
skeletal muscle transgene mylpfa:GFP (von Hofsten et al., 2008) (green) and
nterior to the left, at the level of the posterior hindbrain and anterior spinal cord.
ctedwithmRNAs for MyoD (b), NeuroD2 (c), or M(N) chimera (d). Embryoswere
. Embryos are shown in dorsal views as for control. Arrows in (c) and (d) point to
each construct demonstrates significant overlap of binding sites between the
verlap for the top 15,000 binding sites for each factor.
roD2 and gene regulation has been presented previously (Fong et al., 2012).
s
Figure 3. PBX/MEIS Co-factor Interaction Recruits M(N) Chimera to MyoD Sites and Is Required for Activation of Myogenin
(A) Discriminativemotif enrichment analysis was performed comparing sites bound byM(N) but not shared with NeuroD2 against sites bound by NeuroD2 and not
shared with M(N). M(N)-bound sites, which include sites shared with MyoD, are strongly enriched for a TALE factor motif (MEIS), but not the MyoD private E-box,
whereas a different TALE factor motif is enriched in the NeuroD2 sites.
(B) Schematic of the M(N) chimera with the MyoD His-Cys rich (H/C) and Helix III domains located N-terminal and C-terminal to bHLH domain, respectively.
Induced point mutations are depicted within the H/C region (W96A/C98A) and Helix III (S253P).
(legend continued on next page)
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mutations (M(N)WCS). Single-cell analysis of P19 cells tran-
siently transfected with these constructs showed that these mu-
tants did not activate MYOG expression and appeared to have a
more robust induction of the neuronal tubulin and phenotype
(Figure 3C). In addition, the mutants lost the ability to activate a
reporter driven by a myogenin promoter region containing the
PBX/MEIS binding motif (Figure S2A), an assay used to deter-
mine MyoD-PBX interaction because these proteins do not co-
immunoprecipitate (Berkes et al., 2004).
ChIP-seq following lentiviral transduction of P19 cells demon-
strated that, whereas MyoD and the unmodified chimera both
bound at the Myog promoter, the WC and WCS chimeras, as
well as NeuroD2, did not bind to theMyog promoter (Figure 3D),
similar to what was previously shown for MyoD (Berkes et al.,
2004). Genome-wide analysis of the ChIP-seq data for the
WCS chimera demonstrated a loss of binding to the MyoD-spe-
cific sites that were bound by theM(N) chimera (Figure 4A, upper
panel) and enhanced binding to NeuroD2 sites. Notably, there
also was loss of enrichment for the PBX/MEIS motifs at sites
bound by WCS chimera (Figure S2B), confirming that these mu-
tations were disrupting recruitment to sites with this motif, while
the E-box motif of the WC and WCS chimeras remained un-
changed and identical to NeuroD2 (Figure S2C).
RNA-seq demonstrated that the WC and WCS chimeras no
longer activated many of the MyoD-regulated genes that were
activated by the unmodified chimera, and showed more robust
activation of the NeuroD2-regulated genes (Figure 4A, lower
panel). The WCS chimera activated about 60% of the
NeuroD2-regulated genes, but only about 5% of the MyoD-spe-
cific genes (Figure 4B), indicating that the WCS chimera was
nearly a pure neurogenic transcription factor with only minor re-
sidual myogenic activity. Principal component analysis (PCA)
(Figure 4C) and hierarchical clustering (Figure S3A) also demon-
strated that the M(N) chimera represented an intermediate state
between MyoD and NeuroD2, with weaker activation of MyoD
and NeuroD2 genes, whereas the WC and WCS chimeras
induced an expression pattern close to NeuroD2.
While the decreased activation of myogenic genes by the WC,
S, and WCS chimeras correlated with decreased binding to
MyoD-specific sites, the reason for the increased binding to
NeuroD2-specific sites and activation of neurogenic genes by
these mutants (see Figure 4A) was less clear. To determine
whether binding to MyoD-specific sites simply decreased the
amount of transcription factor available for binding to the Neu-
roD2 sites, we overexpressed the original M(N) chimera or the
WCS chimera by increasing the lentiviral titer 5-fold. Higher
amounts of either the unmodified chimera or the WCS chimera
substantially increased the number of NeuroD2-regulated
genes, with the chimera activating 75% of NeuroD2-regulated
genes and theWCS chimera activating90%of NeuroD2 genes
(Figure 4D; Figure S3B). Therefore, part of the decreased activa-
tion of neurogenic genes by the chimera might reflect decreased(C) Mutation of H/C and/or Helix III domains leads to loss of MYOG expression and
constructs for M(N) chimera (i), M(N) with S253P mutation (ii), M(N) with W96A/C
staining was performed for neuron-specific tubulin (green) and MYOG (red), with
(D) Genome browser screen shot of theMyog promoter demonstrates ChIP-seq pe
See also Figure S3.
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cific sites. However, at these higher titers the chimera main-
tained a substantial activation of MyoD-specific genes (49%)
compared to the WCS chimera (12%). It should be noted that
even at these higher expression levels, the co-expression of
muscle and neuronal genes in the same cell remained rare (Fig-
ure S3C), suggesting that there is an either/or decision that might
limit the abundance of neurogenic gene transcripts in a popula-
tion of cells transduced by the chimera. Finally, another consid-
eration is that the WCS chimera does not have the ‘‘myogenic
code,’’ the AT and K amino acids previously shown to be critical
for muscle gene expression (Bengal et al., 1994; Davis et al.,
1990; Davis and Weintraub, 1992). However, re-introducing
these into the MyoD chimera did not alter its induction of either
neuronal or muscle genes (Figure S4).
DISCUSSION
Our results demonstrate that MyoD can be converted to a potent
neurogenic factor by reprogramming its binding to sites bound
by NeuroD2. The chimera has gained a binding preference for
the NeuroD2 ‘‘private’’ CAGATG E-box that is associated with
gene activation, while losing binding to the MyoD ‘‘private’’
CAGGTG E-box and maintaining binding to the CAGCTG
E-box that is shared by both MyoD and NeuroD2. Previously,
we showed that theNeuroD2private E-box sites aremore strongly
associated with gene activation than binding to the shared E-box,
both in vivo and in reporter constructs driven by paired E-boxes
(Fong et al., 2012). In this report, we demonstrated that both
NeuroD2 and the MyoD chimera have a higher binding affinity
for the NeuroD2 private E-box compared to the shared E-box,
as determined by slower off rates. The increased dwell time at
the private sitemight be sufficient for the increased transcriptional
activity of NeuroD2 and the MyoD chimera on these sites.
MyoD and NeuroD2 have little homology outside of the bHLH
region, and it is interesting that redirecting MyoD from its private
CAGGTG site to the NeuroD2 CAGATG site is sufficient to
convert MyoD from a muscle lineage determination factor to
one that determines the neuronal lineage. This result suggests
that binding location and affinity confers lineage determination
rather than other features of the MyoD or NeuroD2 transcription
factors. It is important to recognize that other factors might
interact with the bHLH region. At this time we do not have any in-
formation regarding alternative E-protein partners, and we
achieve the same results when the transfections are performed
with co-transfected E12 that should drive dimerization to this
common E-protein partner (A.P.F., unpublished data). Therefore,
outside of the bHLH domain and targeting private binding sites,
there does not appear to be any significant lineage determination
function for MyoD or NeuroD2.
This study also confirms the importance of homeodomain
complexes (or complexes that bind to homeodomain motifs),enhanced neuronal differentiation. P19 cells were transfected with expression
98A mutations (iii), or M(N) with W96A/C98A/S253P mutations (iv). Immuno-
DAPI nuclear stain (blue).
aks for bothMyoD andM(N) chimera, but not NeuroD2, M(N)WC, orM(N)WCS.
s
(legend on next page)
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such as PBX/MEIS, for the recruitment of MyoD to a subset of
promoters, such as myogenin. Our prior studies showed that a
PBX/MEIS complex was present at the myogenin promoter in fi-
broblasts, prior to conversion to muscle by MyoD, and that the
WC, S, or WCS mutations in MyoD that disrupt its interaction
with PBX/MEIS also prevent recruitment to the myogenin pro-
moter (Berkes et al., 2004). The findings in the present study
confirm the importance of these interactions at a larger subset
of genes regulated by MyoD and the importance of homeodo-
main proteins in marking this subset for future activation by
MyoD. In addition, the computational identification of a distinct
homeodomain motif associated with sites bound only by Neu-
roD2 and not MyoD or the chimera suggests that NeuroD2might
have its own interacting domain and homeodomain complexes
that guide its binding at a subset of genes. Together, these
results indicate that the ability of a cell to respond to the lineage
instruction of MyoD or NeuroD2 might depend in part on the ho-
meodomain factors that mark specific genes for lineage-specific
activation.
EXPERIMENTAL PROCEDURES
Plasmid Constructs and Neuronal Differentiation
For lentiviral constructs, cDNAs for NeuroD2 and MyoD were cloned into the
GFP site of the pRRL.SIN.cPPT.pGK-GFP.WPRE lentiviral plasmid. cDNA for
M(N) chimera was first synthesized (GenScript) and then sub-cloned into
pCS2 and pRRL as above. W96A/C98A and S253P mutations were intro-
duced by site-directed mutagenesis (Agilent) within the pCS2 backbone
per the manufacturer’s protocol, followed by sub-cloning into pRRL. Replica-
tion-incompetent lentiviral particles were packaged in 293T cells by the Fred
Hutchinson Cancer Research Center Virus Core Facility. P19 cells were in-
fected in MEMa media containing polybrene at a final concentration of
8 mg/ml. After 24 hr, fresh MEMa was added, and, after 48 hr, cells were tran-
sitioned to Neurobasal media (Gibco) containing B27 supplement and 5 mM
glutamine (Farah et al., 2000). Neurobasal media was replaced every 24 hr
until cells were harvested. For transfections, pCS2-MyoD, NeuroD2, or
M(N) were co-transfected with pCL-E12, a construct with a puromycin resis-
tance gene, into P19 cells and 24 hr later, cells were selected with puromycin
for 48 hr, followed by transition to complete Neurobasal media. For reporter
assays, a pair of CAGATG, CAGGTG, or CAGCTG E-boxes were cloned
upstream of the SV40 promoter in pGL3-Pro (Promega) and then co-trans-
fected into P19 cells with the indicated bHLH construct and harvested
48 hr later. * represents p value <0.05 determined by Student’s t test
compared to empty vector.
Immunohistochemistry and Antibodies
Cells were fixed for 10 min with 4% paraformaldehyde in phosphate-buffered
saline (PBS) and permeabilized using 0.5% Triton X-100 in PBS. For immuno-Figure 4. Disruption of the PBX/MEIS Myogenic Co-factor Interactions
Gene Activation by the M(N) Chimera
(A) Scatterplots were generated for ChIP-seq (top row) or RNA-seq (log fold chan
with lentivirus expressing NeuroD2, MyoD, or M(N) chimeras). The NeuroD2-sp
upregulated genes or binding sites are purple. There is increased upregulation o
MyoD genes and binding ofMyoD sites by the chimerawith H/C andHelix III mutat
to the linear regression line.
(B) Venn diagram of log-2 fold upregulated genes demonstrates increased overlap
M(N)WCS compared with M(N) (see Figure 2A).
(C) Principal component analysis of RNA expression profiles demonstrates incre
(D) RNA-seq profiles demonstrate increased activation of bothMyoD andNeuroD2
of NeuroD2 targets with higher expression of M(N)WCS. Upregulated genes are
See also Figure S4.
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bodies raised in rabbits by our lab (1240J, 1168J); (2) anti-MYOD generated
in our lab and previously characterized (Tapscott, et. al., 1988); (3) Tuj1, anti-
neuron-specific tubulin (Covance); (4) Myogenin M-225 (Santa Cruz Biotech-
nology); (5) Desmin D93F5 XP (Cell Signaling Technology); (6) Beta-III tubulin
EPR1568Y (Abcam); (7) myosin heavy chain MF20 (DHB); (8) Internexin 2E3
(Santa Cruz). Secondary antibodies (Jackson ImmunoResearch Laboratories)
were used at 1:500. For western blot, MyoD 5.8A (Santa Cruz) raised against
the C terminus of MyoD was used.
Electromobility Shift Assays
The following sequences represent the forward strands of the oligonucleo-
tides: GA, 5-CAGAGTGACAGATGGCGGCGGG; GG, 5-CAGAGTGACAGGT
GGCGGCGGG; GC, CAGAGTGACAGCTGGCGGCGGG. For dissociation as-
says, radiolabeled oligonucleotide probes were end labeled using PNK and
[g-32P]ATP and cleaned on a Sephadex G-50 spin column. NEUROD2,
MYOD, M(N), and E12 were in vitro translated using the TnT Coupled SP6
Reticulocyte Lysate kit (Promega). In-vitro-translated product was mixed
with probe for 15 min at room temperature. The typical electromobility shift
assay (EMSA) mixture contained 12.5 mM Tris (pH 7.9), 50 mM KCI, 5 mM
MgCl 27.5% glycerol, 0.1 mM EDTA, 1 mM DTT, 0.5 pg of poly(dI-dC).
Following formation of complexes, 100-fold excess of unlabeled oligo was
added for the indicated amount of time, followed by resolution on 6% poly-
acrylamide gel at 200 V for 3 hr at 4C.
ChIP-Seq
ChIP was performed as previously described (Cao et al., 2010). ChIP samples
were validated by qPCR and prepared for sequencing with the NuGENOvation
Ultralow Multiplex System kit. All samples were sequenced on the Illumina
HiSeq 2500 by the Fred Hutchinson Cancer Research Center Genomics
Resource Core Facility.
RNA-Seq
Total RNA was harvested from lentivirally transduced P19 cells that were neu-
ronally differentiated as described above. RNA libraries were subsequently
prepared using oligo-dT selection and sequenced on the Illumina HiSeq
2500. Differentially expressed genes were detected using Bioconductor pack-
age DESeq (Anders and Huber, 2010). GO enrichment analysis was performed
using Bioconductor package GOstats (Falcon and Gentleman, 2007).
ChIP-Seq Analysis
ChIP-seq reads were aligned using Burrows-Wheeler Aligner to the mouse
genome (mm9). Quality control and peak calling were performed using an in
house-developed tool as previously described (Geng et al., 2012).
Motif Analysis
We performed discriminative de novo motif discovery using Bioconductor
package motifRG (Cao et al., 2010; Palii et al., 2011; Yao et al., 2014) to find
motifs that were specifically enriched in MyoD, NeuroD2, M(N) chimera, and
M(N)WCS chimera binding sites. Predicted motifs were annotated based on
matches to Jaspar, Uniprobe, and house-curated motif databases usingResults in Enhanced Binding to NeuroD2 Private Sites and Neuronal
ge relative to GFP, bottom row) binding site intensities in P19 cells transduced
ecific upregulated genes or binding sites are green, and the MyoD-specific
f NeuroD2 genes and binding of NeuroD2 sites and decreased upregulation of
ions (M(N)WCS) comparedwith the unmodified chimera (M(N)). R2 represents fit
between NeuroD2 and M(N)WCS and decreased overlap between MyoD and
ased similarity with NeuroD2 for M(N)WCS relative to both MyoD and M(N).
targets with higher expression of M(N) chimera, but increased expression only
ranked from left to right for NeuroD2 (top panel) or MyoD (bottom panel).
s
software Tomtom in MEME suite (Gupta et al., 2007). To show motif signifi-
cance, we included motif Z scores, which follow normal distribution under
null distribution (e.g., Z score of 5 translates to a p value of 5.7 3 107, and
an adjusted p value of 103 after Bonferroni correction formultiple hypotheses)
(Yao et al., 2014).
Zebrafish Experiments
All experiments involving live zebrafish (Danio rerio) were carried out in compli-
ance with IACUC guidelines. Zebrafish were raised and staged as previously
described (Westerfield, 2007). The Tg(2.2mylpfa:GFP) i135 line that labels
differentiated fast-twitch skeletal muscle has been described (von Hofsten
et al., 2008). Time refers to hours postfertilization (hpf) at 28.5C. mRNAs for
injections into zebrafish embryos were synthesized in vitro, using the
mMessage mMachine kit (Ambion), from the same pCS2-MyoD, NeuroD2,
and M(N) expression constructs used for P19 cell transfections. mRNA injec-
tions were performed using a Narishige IM 300 Microinjector. Embryos were
collected from the Tg(2.2 mylpfa:GFP) strain and injected at the 1-cell stage
with 2 nl of 125 ng/ml mRNAs. Sibling control embryos were not injected with
any mRNAs. Embryos were processed for whole-mount immunostaining as
previously described (Bird et al., 2012) with the following primary antibodies:
anti-Elavl, 1:250 (clone 16A11) (Henion et al., 1996); anti-GFP, 1:300 (Torrey
Pines TP401). Secondary antibodies used were goat anti-mouse Alexa Fluor
568 and goat anti-rabbit Alexa Fluor 488 (1:250, Life Technologies/Molecular
Probes). Embryos were mounted in 70% glycerol in PBS under a coverslip
and imaged using a Leica TCS SP5 confocal microscope.
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